RAC 0.00% $1.69 race oncology ltd

RAC - Charts & Price Action, page-20

  1. 2,940 Posts.
    lightbulb Created with Sketch. 1311
    Not from my understanding. The report just showed how Bisantrene could possibly be used for a more targeted treatment which means you can have lower dose, less side effects, and better efficacy.

    The reports great, but isn't an additional drug to be used in combo broadly like the current proposed trials.

    We've been told they have found synergy with an already approved drug for the upcoming combo trials, but we haven't been told what that drug is. Well as far as I was aware anyway.

    IMO, DYOR, etc
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.